Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are over 18 years old
- You have been diagnosed with a specific type of slow-growing brain tumour called an IDH mutant grade 2 glioma, confirmed by a tissue sample (biopsy)
- You agree to receive the treatment involved in the trial
- You agree to fill in regular questionnaires about how you are feeling and your quality of life
Who may not be able to join:
- You have a cognitive impairment or mental disability that affects your ability to understand questions
- You have dementia or severe memory/thinking difficulties that could make your questionnaire answers unreliable
- You have a serious mental health condition, such as schizophrenia or untreated psychosis, that is not currently under control
- You do not speak or understand the language the questionnaires are written in, and no approved translation is available
- You are unable to read or write
- You refuse to complete the questionnaires, even if you are otherwise willing to take part in the study
- You are taking medications that affect your thinking or mental clarity, such as strong sedatives or antipsychotics, which could affect the reliability of your answers (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sara Morlino, MD, Fondazione IRCCS Istituto Neurologico Carlo Besta
Phone: + 02 2394
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Characterize and compare the experience of patients with IDH-mutant, grade 2 gliomas
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.